In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Cyclin-dependent kinase (CDK) 4/6 inhibitor'
Please login to view adverse reactions.
- (2024): Ortiz-Brugués A+, Ann Oncol 35(10), 915-917
- (2021): Sollena P+, Breast Cancer Res Treat 185(1), 247-253 (16 cases)
- (2023): Minta A+, Support Care Cancer 31(12), 717
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2024): Zhang C+, Am J Cardiovasc Drugs Dec, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2020): Gervaso L+, J Thromb Haemost 18(1), 162-168 [REVIEW]
Hypertransaminasemia (hepatic transaminitis) / elevated transaminases
- (2020): Kovac A+, Cancer Treat Res Commun Aug, Online ahead of print6% (grade 3–4)
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2024): She Y+, Front Pharmacol Apr (e-Collection) (pharmacovigilance / pharmacoepidemiology)
- (2018): Kassem L+, Breast Cancer 25(1), 17 [REVIEW]
Leukocytopenia (leukopenia) / leukocytes (white blood cells) decreased
- (2023): Peng TR+, Thorac Cancer Sep, Online ahead of print45%
Neutropenia (neutrophils decreased)
- (2020): Kovac A+, Cancer Treat Res Commun Aug, Online ahead of print50% (grade 3–4)
- (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4656–33% [REVIEW] (with an aromatase inhibitor)
- (2023): Peng TR+, Thorac Cancer Sep, Online ahead of print51%
- (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4653–9% [REVIEW] (with an aromatase inhibitor)
- (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4653–9% [REVIEW] (with an aromatase inhibitor)
Myalgia/Myositis/Myopathy/Myotoxicity
- (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4655–12% [REVIEW] (with an aromatase inhibitor)
- (2023): Schlam I+, Expert Opin Drug Saf 22(12), 1149-1156 [REVIEW]
- (2021): Raschi E+, Breast Cancer Res Treat 186(1), 219-227 (pharmacovigilance / pharmacoepidemiology)
- (2019): Jazieh KA+, Expert Rev Anticancer Ther 19(11), 917-919 [REVIEW]
Adverse effects / adverse reactions
- (2024): Wekking D+, Semin Oncol Jan, Online ahead of print [REVIEW]
